drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (adoptive T-cell therapy)
drug_description
Allogeneic, off-the-shelf adoptive T-cell therapy composed of donor CMV-specific T lymphocytes expanded ex vivo, stimulated with CMV pp65 peptide and selected via IFN-γ capture; exerts HLA-restricted, antigen-specific TCR recognition with CD4+ helper and CD8+ cytotoxic activity against CMV-infected cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Cytotoxic
drug_category
TCR SELECTED T CELLS
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic donor-derived CMV-specific T lymphocytes expanded ex vivo and selected via IFN-γ capture after CMV pp65 peptide stimulation. These cells use their native, HLA-restricted TCRs to recognize CMV antigens on infected host cells; CD8+ T cells mediate perforin/granzyme cytotoxicity and CD4+ T cells provide helper functions, restoring antigen-specific antiviral immunity.
drug_name
ImmuneCellVir-I
nct_id_drug_ref
NCT06011486